Since DATS increased the levels of cyclin B1 protein, we hypothesized that DATS-treated UMSCC-22A and UMSCC-22B cells would be unable to exit the mitosis phase, on the grounds that a similar phenomenon was reported in prostate cancer cells [21]. This evidence concerns the gene CCNB1 and prostate carcinoma.